Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Non-Current Deffered Revenue (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Non-Current Deffered Revenue for 9 consecutive years, with $34.3 million as the latest value for Q1 2026.

  • For Q1 2026, Non-Current Deffered Revenue fell 58.23% year-over-year to $34.3 million; the TTM value through Mar 2026 reached $34.3 million, down 58.23%, while the annual FY2025 figure was $35.5 million, 61.18% down from the prior year.
  • Non-Current Deffered Revenue hit $34.3 million in Q1 2026 for Bicycle Therapeutics, down from $35.5 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $115.1 million in Q2 2023 and bottomed at $34.3 million in Q1 2026.
  • Average Non-Current Deffered Revenue over 5 years is $75.5 million, with a median of $82.9 million recorded in 2025.
  • Year-over-year, Non-Current Deffered Revenue surged 165.87% in 2023 and then plummeted 61.18% in 2025.
  • Bicycle Therapeutics' Non-Current Deffered Revenue stood at $41.5 million in 2022, then surged by 165.87% to $110.2 million in 2023, then dropped by 17.01% to $91.5 million in 2024, then crashed by 61.18% to $35.5 million in 2025, then dropped by 3.29% to $34.3 million in 2026.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $34.3 million, $35.5 million, and $74.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.